Our study identified PSMD14 as a novel DUB that play a critical role in the chemoresistance of HNSCC and provided a promising therapeutic approach involving the administration of THL to overcome chemoresistance in HNSCC. This evidence concerns the gene ZUP1 and head and neck squamous cell carcinoma.